Diagnostic compositions containing fluorescein carboxylic acid esters comprising a hard gelatine capsule containing (a) a granulate and (b) an outer phase surrounding the granulate, wherein the granulate comprises a fluorescein carboxylic acid ester, sodium carboxymethylamylopectin, microcrystalline cellulose and polyvinylpyrrolidone and the outer phase comprises magnesium stearate, talc and lactose, provide particularly efficacious forms of administration of such fluorescein esters in the deter...

The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pseudooxynicotine compound.

In order to aid in the detection of malignant diseases the sample of a body fluid is incubated with at least two receptors R.sub.1 and R.sub.2 in which a signal change is produced by binding of at least the receptors R.sub.1 and R.sub.2 to the substance to be detected in the sample solution and in which one of the two receptors contains a monoclonal antibody which binds to the amino acid sequence 311 to 335 of cytokeratin 19 and the other receptor contains a monoclonal antibody which binds to th...

Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an alpha-nicotine type compound.

Novel tropane ring system compounds useful for treatment of neurological disorders and for synthetic starting materials for production of cocaine analogs.

The invention relates to a method of treating cardiac ischemic disease using a compound of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, lower alkenyl or N,N-di(lower)alkylaminomethyl, R.sup.2 is hydrogen, lower alkyl or halogen, R.sup.3 is imidazolyl or pyridyl, each of which may have substituent(s) selected from lower alkyl and imino-protective group, and R.sup.4 is hydrogen, lower alkyl, lower alkenyl or hydroxy(lower)alkyl and R.sup.5 is hydrogen, hydroxy or lower alkanoylo...

Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a cytisine compound.

A pharmaceutical composition for the treatment of autoimmune diseases comprising an effective amount of a compound of formula where A is the nucleus of 1-benzyl-indazol-3-yl, R and R', the same or different from each other, are H or an alkyl having from 1 to 5 carbon atoms, R"' is H or an alkyl having from 1 to 4 carbon atoms, or, when R"' is H, of a salt thereof with organic or inorganic pharmaceutically acceptable bases.

Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an (R)-(+)-nicotine compound.